AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Guardant Health Inc (NASDAQ:GH)
48.3 USD
+0.890 1.877%Sponsored Reports
Loading...
| Previous Close (in USD) | 47.41 |
|---|---|
| Change | +0.890 1.877% |
| 52 W H/L (in USD) | 41.060/15.810 |
| EBITDA (in USD) | -401.605M |
| PE Ratio | -- |
| Volume | 1402981 |
| Diluted Eps TTM | -4.02 |
| Total Assets (in USD) | 1786.421M |
|---|---|
| Total Liabilities (in USD) | 1627.737M |
| Revenue TTM (in USD) | 603.725M |
| Cash (in USD) | 1133.537M |
| Market Cap (in USD) | 3,201.173 M |
| Revenue Per Share TTM | 5.171 |
| Gross Profit TTM (in USD) | 293.213M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Employees: 1768
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-CEO & Chairman | 1979 |
| 2. | Dr. AmirAli Talasaz Ph.D. | Co-CEO & Director | 1980 |
| 3. | Mr. Michael Bell | Chief Financial Officer | 1969 |
| 4. | Mr. John G. Saia | Chief Legal Officer | 1973 |
| 5. | Dr. Craig Eagle M.D. | Chief Medical Officer | 1967 |
| 6. | Mr. Christopher Freeman | Chief Commercial Officer of Oncology Bus. | 1974 |
| 7. | Mr. Andy Ament | Sr. VP of Operations | NA |
| 8. | Darya Chudova | Sr. VP of Technology | NA |
| 9. | Mr. Kumud Kalia | Chief Information Officer | NA |
| 10. | Ms. Jennifer Higgins | VP of Public Affairs | NA |
Peers
Sector: Healthcare
Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
TMO
Thermo Fisher Scientific Inc |
-2.420 0.567% | 426.12 | 34.710 | 23.866 | 4.622 | 4.428 | 5.293 | 20.886 |
|
DHR
Danaher Corporation |
+0.640 0.326% | 196.645 | 29.090 | 28.011 | 5.669 | 3.198 | 5.999 | 19.094 |
|
A
Agilent Technologies Inc |
-0.740 0.692% | 105.87 | 34.360 | 26.385 | 6.587 | 7.136 | 6.781 | 23.557 |
|
IDXX
IDEXX Laboratories Inc |
-3.540 0.803% | 438.63 | 49.990 | 45.662 | 11.293 | 27.850 | 11.461 | 34.457 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -653.449M | -384.47M | -245.904M | -69.723M | -84.225M |
| Minority Interest | 0M | -20.9M | 7.5M | 49.6M | 41.8M |
| Net Income | -654.588M | -384.77M | -246.283M | -67.851M | -85.063M |
| Selling General Administrative | 163.956M | 206.64M | 192.77M | 61.399M | 36.192M |
| Gross Profit | 293.213M | 250.741M | 194.195M | 143.655M | 47.429M |
| Reconciled Depreciation | 35.962M | 22.271M | 16.065M | 13.609M | 7.136M |
| Ebit | -544.378M | -411.001M | -254.95M | -82.371M | -90.11M |
| Ebitda | -650.872M | -381.893M | -241.138M | -68.542M | -82.974M |
| Depreciation And Amortization | -106.494M | 29.108M | 13.812M | 13.829M | 7.136M |
| Operating Income | -544.378M | -411.001M | -254.95M | -82.371M | -92.942M |
| Other Operating Expenses | 993.916M | 784.654M | 541.68M | 296.746M | 183.581M |
| Interest Expense | 2.577M | 2.577M | 4.766M | 1.181M | 1.251M |
| Tax Provision | 1.139M | 0.3M | 0.379M | -1.872M | 0.038M |
| Interest Income | 6.069M | 3.93M | 10.171M | 13.741M | 5.266M |
| Net Interest Income | 3.492M | 1.353M | 5.405M | 12.56M | 4.015M |
| Income Tax Expense | 1.139M | 0.3M | 0.379M | -1.872M | 0.038M |
| Total Revenue | 449.538M | 373.653M | 286.73M | 214.375M | 90.639M |
| Total Operating Expenses | 837.591M | 661.742M | 449.145M | 226.026M | 140.371M |
| Cost Of Revenue | 156.325M | 122.912M | 92.535M | 70.72M | 43.21M |
| Total Other Income Expense Net | -109.071M | 26.531M | 9.046M | 12.648M | 4.702M |
| Net Income From Continuing Ops | -654.588M | -384.77M | -246.283M | -67.851M | -84.263M |
| Net Income Applicable To Common Shares | -654.588M | -405.67M | -253.783M | -75.651M | -85.063M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 1786.421M | 1609.985M | 2204.499M | 2271.781M | 962.535M |
| Intangible Assets | 8.979M | 11.727M | 14.207M | 16.2M | 15.414M |
| Other Current Assets | 27.741M | 31.509M | 53.052M | 17.466M | 11.389M |
| Total Liab | 1627.737M | 1549.805M | 1559.494M | 916.186M | 114.542M |
| Total Stockholder Equity | 158.684M | 60.18M | 645.005M | 1298.495M | 798.393M |
| Other Current Liab | 108.261M | -21.878M | 152.925M | 44.287M | 37.12M |
| Common Stock | 0.001M | 0.001M | 0.001M | 0.001M | 0.001M |
| Capital Stock | 0.001M | 0.001M | 0.001M | 0.001M | 0.001M |
| Retained Earnings | -2141.862M | -1662.413M | -1007.825M | -606.592M | -352.809M |
| Good Will | 3.29M | 3.29M | 3.29M | 3.29M | 3.29M |
| Other Assets | - | 36.453M | 60.938M | 17.208M | 4.882M |
| Cash | 1133.537M | 141.647M | 492.202M | 832.977M | 143.228M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 205.917M | 193.22M | 194.687M | 66.809M | 72.734M |
| Current Deferred Revenue | 17.965M | 17.403M | 11.326M | 8.55M | 12.277M |
| Net Debt | 220.227M | 1227.637M | 868.672M | 14.88M | -109.972M |
| Short Term Debt | 27.95M | 21.878M | 12.856M | 6.632M | 7.14M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 1353.764M | 1369.284M | 1360.874M | 847.857M | 33.256M |
| Other Stockholder Equity | 2304.22M | 1742.114M | 1657.593M | 1902.389M | 1150.09M |
| Property Plant Equipment | - | 167.92M | 313.904M | 62.782M | 72.808M |
| Total Current Assets | 1347.106M | 1191.594M | 1114.126M | 1888.361M | 597.358M |
| Long Term Investments | - | 0M | 698.034M | 246.597M | 268.783M |
| Short Term Investments | 35.097M | 869.584M | 440.546M | 961.903M | 379.574M |
| Net Receivables | 88.783M | 97.256M | 97.652M | 53.299M | 47.986M |
| Long Term Debt | 1139.966M | 1137.391M | 1134.821M | 806.292M | - |
| Inventory | 61.948M | 51.598M | 30.674M | 22.716M | 15.181M |
| Accounts Payable | 51.741M | 175.817M | 17.58M | 7.34M | 16.197M |
| Accumulated Other Comprehensive Income | -3.675M | -19.522M | -4.764M | 2.697M | 1.111M |
| Non Currrent Assets Other | 124.184M | 61.453M | 60.938M | 17.208M | 4.882M |
| Non Current Assets Total | 439.315M | 418.391M | 1090.373M | 383.42M | 365.177M |
| Capital Lease Obligations | 213.798M | 231.893M | 226.053M | 41.565M | 40.396M |
| Long Term Debt Total | - | 1137.391M | 1134.821M | 806.292M | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 149.816M | 51.302M | -563.027M | -288.957M | -132.825M |
| Total Cashflows From Investing Activities | 149.816M | -63.155M | -617.086M | -317.57M | -153.028M |
| Total Cash From Financing Activities | -189.093M | -66.824M | 1410.307M | 367.304M | 293.161M |
| Net Income | -654.588M | -384.77M | -246.283M | -67.851M | -84.263M |
| Change In Cash | -842.628M | -340.689M | 689.749M | 2.684M | 67.948M |
| Begin Period Cash Flow | 492.288M | 832.977M | 143.228M | 140.544M | 72.596M |
| End Period Cash Flow | -350.34M | 492.288M | 832.977M | 143.228M | 140.544M |
| Total Cash From Operating Activities | -309.463M | -209.017M | -103.927M | -47.134M | -72.185M |
| Depreciation | 35.962M | 22.271M | 16.065M | 13.609M | 7.136M |
| Other Cashflows From Investing Activities | -23.966M | -39.422M | -17.886M | -9.896M | -132.825M |
| Dividends Paid | - | - | 7.095M | - | 3.156M |
| Change To Inventory | -20.926M | -7.957M | -7.535M | -6.045M | -1.849M |
| Sale Purchase Of Stock | 9.316M | 9.753M | 7.095M | -0.723M | -0.172M |
| Other Cashflows From Financing Activities | -200.963M | -76.431M | 1054.751M | 17.311M | 42.926M |
| Capital Expenditures | 77.461M | 75.035M | 54.059M | 21.285M | 20.203M |
| Change In Working Capital | 61.564M | -40.468M | -47.665M | -6.092M | -1.127M |
| Other Non Cash Items | 152.914M | 29.605M | 18.676M | -2.157M | -0.013M |
| Free Cash Flow | -386.924M | -284.052M | -157.986M | -68.419M | -92.388M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 11 months ago | 3760863 |
| 2. | Vanguard US Growth Investor | 1 year ago | 3140350 |
| 3. | Baillie Gifford US Equity Growth | 1 year ago | 3140350 |
| 4. | Vanguard Small Cap Index | 11 months ago | 2941550 |
| 5. | Eventide Gilead N | 1 year ago | 2717741 |
| 6. | iShares Russell 2000 ETF | 11 months ago | 2634779 |
| 7. | Vanguard Institutional Extnd Mkt Idx Tr | 11 months ago | 1799806 |
| 8. | Vanguard Small Cap Growth Index Inv | 11 months ago | 1661612 |
| 9. | CS (Lux) Digital Health Equity SB USD | 1 year ago | 1650000 |
| 10. | American Funds IS® Growth 1 | 1 year ago | 1618159 |
| 11. | Capital Group Growth Composite | 1 year ago | 1618159 |
| 12. | Capital Group Growth Fnd of Amer Comp | 1 year ago | 1559981 |
| 13. | American Funds Growth Fund of Amer A | 1 year ago | 1559981 |
| 14. | Baillie Gifford American B Inc | 1 year ago | 1460113 |
| 15. | Eventide Healthcare & Life Sciences I | 1 year ago | 1168310 |
| 16. | Fidelity Small Cap Index | 1 year ago | 1153462 |
| 17. | iShares Russell 2000 Growth ETF | 11 months ago | 953425 |
| 18. | Fidelity Blue Chip Growth | 1 year ago | 728423 |
| 19. | Fidelity Extended Market Index | 1 year ago | 704842 |
| 20. | Franklin Biotechnology Discv A(acc)USD | 11 months ago | 704526 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 1 year ago | 11436026 |
| 2. | BlackRock Inc | 1 year ago | 10831716 |
| 3. | Baillie Gifford & Co Limited. | 1 year ago | 6232104 |
| 4. | Deep Track Capital, LP | 1 year ago | 6000000 |
| 5. | Cadian Capital Management LP | 1 year ago | 5792779 |
| 6. | FMR Inc | 1 year ago | 5251349 |
| 7. | Eventide Asset Management, LLC | 1 year ago | 4179432 |
| 8. | Temasek Holdings Ltd. | 1 year ago | 4111172 |
| 9. | Capital Research & Mgmt Co - Division 3 | 1 year ago | 3822939 |
| 10. | Parkwood LLC | 1 year ago | 2800000 |
| 11. | State Street Corporation | 1 year ago | 2572324 |
| 12. | Geode Capital Management, LLC | 1 year ago | 2513703 |
| 13. | BRAIDWELL LP | 1 year ago | 2476804 |
| 14. | Morgan Stanley - Brokerage Accounts | 1 year ago | 2458282 |
| 15. | Fidelity International Ltd | 1 year ago | 1970988 |
| 16. | Credit Suisse First Boston (CSFB) | 1 year ago | 1844796 |
| 17. | Goldman Sachs Group Inc | 1 year ago | 1819540 |
| 18. | T. Rowe Price Associates, Inc. | 1 year ago | 1545114 |
| 19. | Franklin Resources Inc | 1 year ago | 1369009 |
| 20. | Charles Schwab Investment Management Inc | 1 year ago | 1277099 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
